You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: R

    DESCRIPTION Based on the prevailing evidence we believe that a highly effective vaccine for HIV prophylaxis must induce long lasting broadly cross reactive antibody responses to envelope that exhibit antiviral activity as well as multi antigen polyfunctional CD and CD T cell responses that produce antiviral chemokines and cytokines and are possibly biased towards an effector memory phenot ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Aptamer-Based Detection of Cardiac Biomarker Glycosylation States Using APT-SNAP

    SBC: Proteovista LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Aptamer Based Detection of Cardiac Biomarker Glycosylation States Using APT SNAP Arrays PIs Christopher L Warren and Mary S Ozers The presence of cardiac related biomarkers in patient biospecimens can provide important insight into diagnosis of cardiovascular disease its progression and optimal therapies for treatment Most of the cardiac biomarkers in cli ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a novel highly effective influenza vaccine

    SBC: Flugen, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Staphylococcus aureus is a Gram positive human pathogen that causes a wide range of infections from skin and soft tissue infections SSTI to life threatening sepsis and pneumonia The pathogenicity of S aureus is dependent on numerous virulence factors including cell surface proteins and polysaccharides as well as secreted toxins An important group of thes ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Inhibitors Targeting Early Steps of Human Cytomegalovirus Replication

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Human cytomegalovirus HCMV infection is a major cause of morbidity and mortality in immunosuppressed patients especially recipients of solid organ or bone marrow transplants HCMV infection of neonates is associated with deafness mental retardation and mortality Although five anti viral drugs GCV val GCV CDV PFA Foscarnet have been approved and lice ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Mobile Health App to Reduce Diabetes in Latina Women with Prior Gestational Diabe

    SBC: Environment And Health Group, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant Hispanic women have the highest lifetime risk for type diabetes T DM A window of opportunity for preventing T DM exists for women with pregnancies complicated by gestational diabetes mellitus GDM Women with prior GDM face increased risk of T DM Hispanic women are at increased risk of GDM and those with GDM have higher relative risks for developing T D ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Novel Substrate to Amplify Growth Factor Impact on hPSC Differentiation

    SBC: PRIMORIGEN BIOSCIENCES INC.            Topic: 300

    DESCRIPTION provided by applicant Primorigen Biosciences R Project Abstract Primorigen will use SBIR funds to develop a paradigm changing technology for expansion and directed differentiation of human pluripotent stem cells hPSCs using a novel peptide that dramatically reduces costs by amplifying the impact of endogenous growth factors and minimizing the need for exogenous growth factors Th ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Automating mosquito microdissection for a malaria PfSPZ vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION Malaria causes andgt million clinical cases and million deaths annually is responsible for andgt loss of GDP in Africa and is a serious concern for travelers and military personnel A highly effective vaccine is desperately needed and radiation attenuated Plasmodium falciparum Pf sporozoites SPZ and non attenuated PfSPZ with chloroquine chemoprophylaxis ChemoProphylax ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government